ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.65
0.48%
US Tech 100
18,318.00
0.95%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36645
-0.50%
Bitcoin
68,946.56
1.50%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cingulate Inc (CINGW)

  7. Cingulate Inc (CINGW) News

CINGW

Cingulate (CINGW)

Cingulate Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CINGW
DateTimeSourceHeadlineSymbolCompany
05/23/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CINGWCingulate Inc
05/23/20244:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CINGWCingulate Inc
05/21/20248:00AMGlobeNewswire Inc.FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHDNASDAQ:CINGWCingulate Inc
05/17/20244:01PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CINGWCingulate Inc
05/13/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
05/08/20246:15AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CINGWCingulate Inc
05/08/20246:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
05/08/20246:00AMGlobeNewswire Inc.Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
04/30/20244:45AMGlobeNewswire Inc.Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessNASDAQ:CINGWCingulate Inc
04/16/20244:00PMGlobeNewswire Inc.Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024NASDAQ:CINGWCingulate Inc
04/01/20247:00AMGlobeNewswire Inc.Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
03/19/20243:45PMGlobeNewswire Inc.Cingulate to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
03/06/20245:45AMGlobeNewswire Inc.Cingulate to Attend DCAT Week 2024 in New York CityNASDAQ:CINGWCingulate Inc
02/13/20245:45AMGlobeNewswire Inc.Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsNASDAQ:CINGWCingulate Inc
02/06/20243:15PMGlobeNewswire Inc.Cingulate Announces Closing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
02/02/20248:15AMGlobeNewswire Inc.Cingulate Announces Pricing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
01/29/20247:00AMGlobeNewswire Inc.Longtime Cingulate Controller Jennifer Callahan Promoted to CFONASDAQ:CINGWCingulate Inc
01/29/20245:45AMGlobeNewswire Inc.Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketNASDAQ:CINGWCingulate Inc
12/01/20238:00AMGlobeNewswire Inc.Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)NASDAQ:CINGWCingulate Inc
11/13/20233:15PMGlobeNewswire Inc.Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
10/17/20231:22PMGlobeNewswire Inc.Cingulate to Host CNS Key Opinion Leader Panel in New York CityNASDAQ:CINGWCingulate Inc
09/21/202312:30PMGlobeNewswire Inc.Cingulate Inc. to Present at the LD Micro Main Event XVINASDAQ:CINGWCingulate Inc
09/13/20233:15PMGlobeNewswire Inc.Cingulate Announces Closing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
09/11/20238:22AMGlobeNewswire Inc.Cingulate Announces Pricing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
09/11/20235:00AMGlobeNewswire Inc.Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
09/08/20233:31PMGlobeNewswire Inc.Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a PremiumNASDAQ:CINGWCingulate Inc
09/05/20237:00AMGlobeNewswire Inc.Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023NASDAQ:CINGWCingulate Inc
08/14/20233:15PMGlobeNewswire Inc.Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
07/11/20237:00AMGlobeNewswire Inc.Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
06/29/20237:00AMGlobeNewswire Inc.Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and AugustNASDAQ:CINGWCingulate Inc
 Showing the most relevant articles for your search:NASDAQ:CINGW

Your Recent History

USOTC
TXTM
ProText Mobility (PK)
USOTC
DPLS
DarkPulse (PK)
NASDAQ
IOVA
Iovance Biotherapeutics
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
NLST
Netlist (QB)
AMEX
SPY
SPDR S&P 500
USOTC
BIEL
Bioelectronics (PK)
USOTC
AHRO
Authentic (CE)
USOTC
AESO
Atlantic Energy Solutions (PK)
USOTC
CNNA
Cann American (CE)
NASDAQ
NB
NioCorp Developments
USOTC
CLNV
Clean Vision (QB)
USOTC
INKW
Greene Concepts (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved